Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

Perjeta has become one of Roche’s fastest-growing and top-selling drugs, thanks in no small part to data from the APHINITY trial which showed that adding it to Herceptin can improve disease-free ...

At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial ...

Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...

In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses results from an interim analysis of the DESTINY-Breast09 trial, which were presented at ASCO Annual Meeting.The ...

Perjeta (pertuzumab) is already available for use in HER-2 positive patients with metastatic breast cancer when combined with Herceptin and docetaxel, but is only available through the Cancer ...

The Best of ASCO UAE Conference 2025, organised by SEHA, part of PureHealth Group, in collaboration with Tawam Hospital, ...

CHICAGO -- First-line trastuzumab deruxtecan (T-DXd) combined with pertuzumab (Perjeta) improved progression-free survival (PFS) in HER2-positive locally advanced or metastatic breast cancer ...

The pathology report from my surgery, from testing the lesion and lymph nodes removed, show no residual cancer. I knew the odds of this happening was only 50/50 because hormone-positive tumours don't ...

Tolaney will present the most anticipated results for Monday with DESTINY-Breast09 (NCT04784715), which compares T-DXd with or without pertuzumab (Perjeta) against a taxane chemotherapy ...

In the trial, treatment with Enhertu and Perjeta delayed cancer growth for longer than the established regimen of Perjeta, Herceptin and chemotherapy, which is known by the acronym THP.